Can patients with depression undergo dust mite desensitization?

Patients with depression may undergo house dust mite allergen immunotherapy when their condition is stable and there are no contraindications to desensitization. This treatment targets diseases triggered by house dust mite allergies and does not directly conflict with depression itself, but it should only be administered after a comprehensive evaluation by a qualified physician. If significant mood fluctuations or worsening allergic reactions occur during immunotherapy, prompt medical consultation is recommended.

The core of house dust mite immunotherapy is gradually training the body to tolerate mite allergens, thereby reducing allergic symptoms. Its mechanism does not interfere with antidepressant treatments. For patients suffering from both house dust mite allergy and depression, controlling allergic symptoms can improve sleep quality and reduce physical discomfort, thus indirectly supporting emotional stability.

However, if a patient's depression is unstable—such as in cases of severe low mood, suicidal tendencies, or undergoing intensive antidepressant therapy—priority should be given to managing psychiatric symptoms, and immunotherapy should be postponed. Additionally, patients who are allergic to components of the immunotherapeutic agent or who have severe cardiopulmonary conditions should avoid this treatment.

During immunotherapy, patients must strictly follow medical instructions for regular medication, maintain clean and dry living environments to minimize dust mite growth, and avoid exposure to other allergens. It is also important to continue the existing antidepressant regimen, maintain regular daily routines, and keep emotions stable, all of which help achieve dual benefits in both desensitization and emotional regulation.